Consider the following statements about IPR regime:
Which of the above statements is/are incorrect
Consider the following statements about IPR regime:
Which of the above statements is/are incorrect
The correct option is A 1 only
The government has “privately reassured” USA, that it would not use compulsory licences (CLs) for commercial purposes — indicating that India’s patent office will take a more restrained approach in handing out licences to domestic players to produce cheaper versions of patented drugs.
Background:
The WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) sets out specific provisions like attempts to obtain a license under reasonable commercial terms must have failed over a reasonable period of time that shall be followed if a compulsory license is issued. The principal requirement for the issue of a compulsory license is that.
The country's first compulsory licence has been granted to allow Natco to make and sell in India, a similar version of Bayer's Nexavar, an advanced kidney cancer drug. The judgment reasoned that the patent-holder, Bayer, had not met the reasonable requirement of the public at reasonable price.
The pharmaceutical company’s patent for a medicine lapses after twenty years, when it loses the right to be the sole manufacturer, seller and distributor of the product. In such a scenario, pharmaceutical companies producing generic medicines can step in
1 only
The government has “privately reassured” USA, that it would not use compulsory licences (CLs) for commercial purposes — indicating that India’s patent office will take a more restrained approach in handing out licences to domestic players to produce cheaper versions of patented drugs.
Background:
The WTO’s Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) sets out specific provisions like attempts to obtain a license under reasonable commercial terms must have failed over a reasonable period of time that shall be followed if a compulsory license is issued. The principal requirement for the issue of a compulsory license is that.
The country's first compulsory licence has been granted to allow Natco to make and sell in India, a similar version of Bayer's Nexavar, an advanced kidney cancer drug. The judgment reasoned that the patent-holder, Bayer, had not met the reasonable requirement of the public at reasonable price.
The pharmaceutical company’s patent for a medicine lapses after twenty years, when it loses the right to be the sole manufacturer, seller and distributor of the product. In such a scenario, pharmaceutical companies producing generic medicines can step in
